spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  vulvar intraepithelial neoplasia 

 HSMN NewsFeed - 1 Jul 2011
Merck Receives Approval to Market GARDASIL(R), ZOLINZA(R) and CUBICIN(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Dec 2010
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 17 Oct 2009
FDA Approves GARDASIL(R) for Use in Boys and Young Men
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jan 2009
Merck & Co., Inc. Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL(R) in Women Ages 27 through 45
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2008
Graceway Pharmaceuticals Reports Study in New England Journal of Medicine: ALDARA(R) (imiquimod) Cream, 5% demonstrated a reduction in lesion size in patients with vulvar intraepithelial neoplasia (VIN)
Biopharmaceuticals
 HSMN NewsFeed - 17 May 2007
Data Published in The Lancet Show GARDASIL(R) was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
Merck's New Cervical Cancer Vaccine, GARDASIL(R), Unanimously Recommended by CDC Advisory Panel for Vaccination of Girls and Women 11 to 26 Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 May 2006
FDA Advisory Committee Votes Unanimously That Clinical Data Support the Efficacy and Safety of GARDASIL(R), Merck's Investigational Cervical Cancer Vaccine
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
vulvar intraepithelial neoplasia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.